IBB returns by year
iShares Biotechnology ETF has returned +7.3% annually (CAGR) since 2002. Calendar-year, monthly and weekly total returns for iShares Biotechnology ETF (IBB) below, through July 24, 2026 — the most recent year is year-to-date.
iShares Biotechnology ETF returns by year (2002–2026)#
Calendar-year returns with each year's path and its dividend contribution (dividend return = total minus price return).
| Year | Start price | End price | Path | Dividend | Total return |
|---|---|---|---|---|---|
| 2026YTD | $168.77 | $188.14 | +0.1% | +11.6% | |
| 2025 | $132.21 | $168.77 | +0.3% | +28.0% | |
| 2024 | $135.85 | $132.21 | +0.3% | -2.4% | |
| 2023 | $131.29 | $135.85 | +0.3% | +3.8% | |
| 2022 | $152.62 | $131.29 | +0.3% | -13.7% | |
| 2021 | $151.49 | $152.62 | +0.2% | +1.0% | |
| 2020 | $120.51 | $151.49 | +0.3% | +26.0% | |
| 2019 | $96.43 | $120.51 | +0.2% | +25.2% | |
| 2018 | $106.77 | $96.43 | +0.2% | -9.5% | |
| 2017 | $88.46 | $106.77 | +0.4% | +21.1% | |
| 2016 | $112.78 | $88.46 | +0.1% | -21.4% | |
| 2015 | $101.12 | $112.78 | +0.0% | +11.6% |
Total return by period
Methodology#
Returns are total returns (dividends reinvested), computed from IBB's split- and dividend-adjusted closes. The bar chart switches between annual and monthly periods. Annualized return is the compound annual growth rate over the full period. The current year is year-to-date. See also the periodic table of returns. Past performance does not predict future returns; not investment advice.
See also: S&P 500 · Nasdaq-100 · Dow Jones · Russell 2000 · US Bond Market · Gold · Silver · Bitcoin · Ethereum
FAQ
- What is iShares Biotechnology ETF's average annual return?
- Since 2002, iShares Biotechnology ETF (IBB) has returned about 7.3% a year (the compound annual growth rate) and an average calendar-year return of 10.1%.
- What were iShares Biotechnology ETF's best and worst years?
- Over 2002–2026, the best year was 2013 (+65.5%) and the worst was 2002 (-45.8%).
- How often is iShares Biotechnology ETF up in a year?
- 18 of the 24 full years since 2002 were positive — about 75% of the time.